SARS-CoV-2 vaccination and phase 1 cancer clinical trials

TA Yap; LL Siu; E Calvo; Martijn Lolkema; PM Lorusso; JC Soria; R Plummer; JS de Bono; J Tabernero; U Banerji

doi:10.1016/S1470-2045(21)00017-6

SARS-CoV-2 vaccination and phase 1 cancer clinical trials

TA Yap
, LL Siu
, E Calvo
, Martijn Lolkema
, PM Lorusso
, JC Soria
, R Plummer
, JS de Bono
, J Tabernero
, U Banerji

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

11 Citations (Scopus)

69 Downloads (Pure)

Original language	English
Pages (from-to)	298-301
Number of pages	4
Journal	The Lancet Oncology
Volume	22
Issue number	3
DOIs	https://doi.org/10.1016/S1470-2045(21)00017-6
Publication status	Published - Mar 2021

Bibliographical note

Funding Information:
We declare no competing interests related to the study, with full details of other competing interests listed in the appendix . TAY thanks the MD Anderson Cancer Center for support grant P30 CA016672 and the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy at the MD Anderson Cancer Center for support grant 1U01 CA180964. RP, JSDB, and UB thank the Experimental Cancer Centre and National Institute of Health Biomedical Research Centre for infrastructural funding.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC OR-01

Access to Document

10.1016/S1470-2045(21)00017-6

Repub_135267.pdfFinal published version, 306 KB

Cite this

@article{b30cf5db631d4fa9bde1647475079adb,

title = "SARS-CoV-2 vaccination and phase 1 cancer clinical trials",

author = "TA Yap and LL Siu and E Calvo and Martijn Lolkema and PM Lorusso and JC Soria and R Plummer and \{de Bono\}, JS and J Tabernero and U Banerji",

note = "Funding Information: We declare no competing interests related to the study, with full details of other competing interests listed in the appendix . TAY thanks the MD Anderson Cancer Center for support grant P30 CA016672 and the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy at the MD Anderson Cancer Center for support grant 1U01 CA180964. RP, JSDB, and UB thank the Experimental Cancer Centre and National Institute of Health Biomedical Research Centre for infrastructural funding.",

year = "2021",

month = mar,

doi = "10.1016/S1470-2045(21)00017-6",

language = "English",

volume = "22",

pages = "298--301",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "3",

}

TY - JOUR

T1 - SARS-CoV-2 vaccination and phase 1 cancer clinical trials

AU - Yap, TA

AU - Siu, LL

AU - Calvo, E

AU - Lolkema, Martijn

AU - Lorusso, PM

AU - Soria, JC

AU - Plummer, R

AU - de Bono, JS

AU - Tabernero, J

AU - Banerji, U

N1 - Funding Information: We declare no competing interests related to the study, with full details of other competing interests listed in the appendix . TAY thanks the MD Anderson Cancer Center for support grant P30 CA016672 and the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy at the MD Anderson Cancer Center for support grant 1U01 CA180964. RP, JSDB, and UB thank the Experimental Cancer Centre and National Institute of Health Biomedical Research Centre for infrastructural funding.

PY - 2021/3

Y1 - 2021/3

UR - https://www.scopus.com/pages/publications/85101722520

U2 - 10.1016/S1470-2045(21)00017-6

DO - 10.1016/S1470-2045(21)00017-6

M3 - Article

SN - 1470-2045

VL - 22

SP - 298

EP - 301

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 3

ER -

SARS-CoV-2 vaccination and phase 1 cancer clinical trials

Bibliographical note

UN SDGs

Research programs

Access to Document

Other files and links

Cite this